Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06282965 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury

A Phase 1 study of Traumatic Brain Injury, sponsored by University of Arizona.

Recruiting
Registry status
Phase 1
Development phase
90
Enrollment target
1
Study location

NCT06282965 is a Phase 1 study of Traumatic Brain Injury that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 90 participants, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06282965, a Phase 1 study of Traumatic Brain Injury, is actively recruiting participants, sponsored by University of Arizona.

RECRUITING
Registry status
Phase 1
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to test the safety of the drug Angiotensin (1-7) and learn whether it works well as a treatment in people who have suffered a moderate to severe traumatic brain injury (TBI). The main questions this trial aims to answer are: * Is Angiotensin (1-7) safe? * Does Angiotensin (1-7) improve mental functioning and reduce physical signs of brain damage in people who have suffered a moderate to severe TBI? Participants will: * Complete 21 days of study treatment consisting of a once-daily injection. * Provide blood samples. * Undergo two magnetic resonance imaging (MRI) scans of the brain. * Complete specific tasks and questionnaires that allow researchers to evaluate the participant's brain and psychological functioning. Researchers will compare three groups: two groups that receive different doses of Angiotensin (1-7) and one group that receives a look-alike treatment with no active drug. This will allow researchers to see if the drug has any negative effects and whether it improves mental functioning and physical signs of brain damage after a TBI.

Conditions Studied

Traumatic Brain Injury

Interventions

  • DRUG Angiotensin (1-7)
  • DRUG Sterile saline

Study Locations (1)

Arizona

  • University of Arizona - Tucson

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2024-05-28
Est. Completion 2027-09
Phase Phase 1

Sponsor

University of Arizona

349 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06282965

The ClinicalTrials.gov registry entry for NCT06282965 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (68% lower). The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Traumatic Brain Injury appearing as the primary indexed condition, and to 2 interventions - of which Angiotensin (1-7) is the first listed.

NCT06282965 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT06282965 about?

NCT06282965 is a clinical study titled "Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury". The goal of this clinical trial is to test the safety of the drug Angiotensin (1-7) and learn whether it works well as a treatment in people who have suffered a moderate to severe traumatic brain injury (TBI). The main questions this trial aims to answer are: * Is Angiotensin (1-7) safe? * Does An...

What is the current status of trial NCT06282965?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2024-05-28. Estimated completion is 2027-09.

What conditions does trial NCT06282965 study?

This clinical trial studies the following conditions: Traumatic Brain Injury.

What interventions are being tested in trial NCT06282965?

The interventions under investigation include: Angiotensin (1-7) (DRUG), Sterile saline (DRUG).

Who is sponsoring clinical trial NCT06282965?

This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06282965 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Traumatic Brain Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Traumatic Brain Injury

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.